Additionally, PDTCs and ATCs are characterized by mutations in the PTEN tumor suppressor gene, with the consequent constitutive activation of PI3K/AKT signaling pathways, as well in TERT and TP53 genes, whose dysregulation leads to tumor heterogeneity, dedifferentiation, and progression [14] (Figure 1). Here, PTEN is linked to neoplasm.